Demonstrates enhanced stability and bioactivity of quercetin in topical formulations, suggesting a breakthrough in therapeutic applications.
Quercetin, a plant-derived flavonoid with potent antioxidant and anti-inflammatory properties, is limited for topical use by its poor aqueous solubility, low bioavailability, and chemical instability. This research developed and validated a formulation-driven strategy to stabilize quercetin by encapsulating it in lipid nanoparticles (QLNs) and embedding these in a Carbopol hydrogel, providing comprehensive physicochemical and functional stability data. A fully validated HPLC-PDA assay was used to quantify quercetin in the nanoparticle–hydrogel matrix. In vitro bioactivity testing showed notable antioxidant activity (DPPH IC50 6.84 ± 0.12 µg/mL; ABTS IC50 4.04 ± 0.08 µg/mL; FRAP 301.46 ± 3.68 µg/mL) and an anti-inflammatory effect in LPS-stimulated RAW264.7 macrophages (1 µM quercetin reduced NO from 50.72 ± 2.00 µM to 41.57 ± 3.12 µM, p < 0.05). Forced degradation mapping across acidic, basic, oxidative, and photolytic conditions defined degradation pathways (complete loss in 1 N NaOH at 24 h; greater retention in 1 N HCl, 3% H2O2, and UV-254). QLN–hydrogel formulations remained physically and chemically stable through heating–cooling cycles and 180-day storage at multiple temperatures, retaining >90% quercetin and preserving antioxidant and anti-inflammatory activities (<10% reduction). These results establish a robust, application-ready approach for maintaining quercetin’s chemical integrity and bioactivity in topical formulations.
No takes yet. Share an insight, caveat, or question.
Tangjidapichai et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: